Transmission of viral hepatitis by blood and blood derivatives: current risks, past heritage.
For more than 40 years in the history of transfusion medicine, transmission of viral hepatitis from infected donors to recipients has been a frequent and serious adverse effect of the administration of blood components and plasma derivatives. This epidemic is now over, at least in developed and resource-rich countries. Hence, the attention of clinicians and investigators now focuses mainly on the measures to reduce the residual risk, on the possible emergence of novel or undiscovered agents causing post-transfusion hepatitis, and on the long-term outcome of patients who became infected more than ten years ago. The present article reviews these issues.
Prati
D
D
Blood Transfusion and Transplantation Immunology Centre, Postgraduate School of Gastroenetrology, IRCCS Ospedale Maggiore, University of Milan, Italy. dprati@yahoo.com
D001688:Biological Products / Q000009:adverse effects*; D001803:Blood Transfusion / Q000592:standards; D019049:Developed Countries; D005821:Genetic Techniques / Q000191:economics; D006525:Hepatitis, Viral, Human / Q000635:transmission*; D006801:Humans; D017063:Outcome Assessment, Health Care; D012306:Risk; D065227:Transfusion Reaction
D001688:Biological Products